Phaseline

Targets › FASLG

FASLG (Tumor necrosis factor ligand superfamily member 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.

Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. (UniProt, P48023)

Open in Phaseline: the race on FASLG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Providence Health & ServicesM3T01
Fully human IgG4/kappa monoclonal antibody targeting FasL (Fas ligand)
FASLGPhase 1Advanced Solid TumorsFeb 2028

Conditions

Advanced Solid Tumors (1)

Modalities

mixed (1)

Companies

Providence Health & Services (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.